Dry eye syndrome: developments and lifitegrast in perspective
Ivonne V Lollett,1 Anat Galor2,3 1University of Miami, Miller School of Medicine, Miami, FL, 2Ophthalmology Department, Miami Veterans Administration Medical Center, Miami, FL, 3Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, FL, USA Abstract: Dry eye (DE) is a...
Guardado en:
Autores principales: | Lollett IV, Galor A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d2c89b52e9374f50bb519291a3979aa2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016) -
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021) -
The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian J, et al.
Publicado: (2020) -
Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019) -
Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah RT, et al.
Publicado: (2019)